<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68697">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01753440</url>
  </required_header>
  <id_info>
    <org_study_id>AHEPA_CTL_01</org_study_id>
    <nct_id>NCT01753440</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy</brief_title>
  <official_title>Study on the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Implantation Combined With Bypass Grafting in Patients With Coronary Artery Disease and Ischemic Cardiomyopathy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <authority>Greece: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate safety and efficacy of intramyocardial
      implantation of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy
      at the time of coronary artery bypass grafting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Left ventricular ejection fraction</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in left ventricular ejection fraction assesed with echocardiography after intramyocardial implantation of allogeneic mesenchymal stem cells.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial segmental perfusion</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in segmental perfusion as assesed with SPECT after intramyocardial implantation of allogeneic mesenchymal stem cells.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality</measure>
    <time_frame>one year</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause morbidity</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>major adverse cardiac and cerebrovascular events</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Ischemic Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Stem cells implantation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with severe coronary artery disease with ischemic cardiomyopathy managed with concomitant coronary artery bypass grafting and intramyocardial administration of allogeneic mensenchymal stem cells.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Intramyocardial implantation of allogeneic mesenchymal stem cells</intervention_name>
    <description>Intramyocardial implantation of allogeneic mesenchymal stem cells</description>
    <arm_group_label>Stem cells implantation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 18 to 75 years

          -  Severe coronary artery disease amenable to surgical revascularization according to
             current guidelines

          -  History of acute myocardial infarction at least 14 days previously

          -  Left ventricular ejection fraction (LVEF) ≤ 40% as assessed with echocardiography

          -  Distinct area of dyskinetic or akinetic left ventricular myocardium corresponding
             with the infarct localization

          -  Patient's informed consent obtained

        Exclusion Criteria:

          -  Emergency operation

          -  Debilitating chronic disease (eg. malignancy or terminal renal failure)

          -  Concomitant valve surgery

          -  Previous cardiac surgery

          -  Malignant ventricular arrhythmias

          -  Haematologic disease

          -  Woman in reproductive age

          -  Severe psychiatric illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyriakos Anastasiadis, MD, DSc, FETCS</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHEPA University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Polychronis Antonitsis, MD, DSc</last_name>
    <phone>+ 30 2310994871</phone>
    <email>antonits@auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>546 36</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Polychronis Antonitsis, MD, DSc</last_name>
      <phone>+ 30 2310 994871</phone>
      <email>antonits@auth.gr</email>
    </contact>
    <investigator>
      <last_name>Polychronis Antonitsis, MD, DSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Hare JM, Fishman JE, Gerstenblith G, DiFede Velazquez DL, Zambrano JP, Suncion VY, Tracy M, Ghersin E, Johnston PV, Brinker JA, Breton E, Davis-Sproul J, Schulman IH, Byrnes J, Mendizabal AM, Lowery MH, Rouy D, Altman P, Wong Po Foo C, Ruiz P, Amador A, Da Silva J, McNiece IK, Heldman AW. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012 Dec 12;308(22):2369-79.</citation>
    <PMID>23117550</PMID>
  </reference>
  <reference>
    <citation>Anastasiadis K, Antonitsis P, Doumas A, Koliakos G, Argiriadou H, Vaitsopoulou C, Tossios P, Papakonstantinou C, Westaby S. Stem cells transplantation combined with long-term mechanical circulatory support enhances myocardial viability in end-stage ischemic cardiomyopathy. Int J Cardiol. 2012 Mar 22;155(3):e51-3. doi: 10.1016/j.ijcard.2011.07.062. Epub 2011 Aug 17.</citation>
    <PMID>21852003</PMID>
  </reference>
  <reference>
    <citation>Menasche P. Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol. 2011 Feb;50(2):258-65. doi: 10.1016/j.yjmcc.2010.06.010. Epub 2010 Jun 30. Review.</citation>
    <PMID>20600097</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Kyriakos Anastasiadis</investigator_full_name>
    <investigator_title>Associate Professor Kyriakos Anastasiadis</investigator_title>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>heart failure</keyword>
  <keyword>stem cells implantation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
